Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,876
edits
Changes
Jump to navigation
Jump to search
Line 4:
Line 4: − + + + + Line 14:
Line 17: − + − + − + Line 165:
Line 168: − + Line 245:
Line 248: − + Line 332:
Line 335: − + − +
HAEM5:Breast implant-associated anaplastic large cell lymphoma (view source)
Revision as of 14:21, 13 December 2023
, 14:21, 13 December 2023no edit summary
{{Under Construction}}
{{Under Construction}}
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Breast Implant-Associated Anaplastic Large Cell Lymphoma]].
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Breast Implant-Associated Anaplastic Large Cell Lymphoma]].
}}</blockquote>
}}</blockquote>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
==Primary Author(s)*==
==Primary Author(s)*==
__TOC__
__TOC__
==Cancer Category/Type==
==Cancer Category / Type==
* [[Mature T- and NK-cell Neoplasms]]
* [[HAEM4:Mature T- and NK-cell Neoplasms]]
==Cancer Sub-Classification / Subtype==
==Cancer Sub-Classification / Subtype==
* [[Anaplastic Large Cell Lymphoma, ALK-Negative]]
* [[HAEM5:ALK-negative anaplastic large cell lymphoma]]
==Definition / Description of Disease==
==Definition / Description of Disease==
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Mw|first=Clemens|last2=Ed|first2=Jacobsen|last3=Sm|first3=Horwitz|date=2019|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)|url=https://pubmed.ncbi.nlm.nih.gov/30715173/|language=en|pmid=30715173}}</ref><ref>{{Cite journal|last=Mc|first=Ferrufino-Schmidt|last2=Lj|first2=Medeiros|last3=H|first3=Liu|last4=Mw|first4=Clemens|last5=Kk|first5=Hunt|last6=C|first6=Laurent|last7=J|first7=Lofts|last8=Mb|first8=Amin|last9=S|first9=Ming Chai|date=2018|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29194092/|language=en|pmid=29194092}}</ref><ref name=":0" /></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Mw|first=Clemens|last2=Ed|first2=Jacobsen|last3=Sm|first3=Horwitz|date=2019|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)|url=https://pubmed.ncbi.nlm.nih.gov/30715173/|language=en|pmid=30715173}}</ref><ref>{{Cite journal|last=Mc|first=Ferrufino-Schmidt|last2=Lj|first2=Medeiros|last3=H|first3=Liu|last4=Mw|first4=Clemens|last5=Kk|first5=Hunt|last6=C|first6=Laurent|last7=J|first7=Lofts|last8=Mb|first8=Amin|last9=S|first9=Ming Chai|date=2018|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29194092/|language=en|pmid=29194092}}</ref><ref name=":0" /></blockquote>
</blockquote>
</blockquote>
==Individual Region Genomic Gain/Loss/LOH==
==Individual Region Genomic Gain / Loss / LOH==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
</blockquote>
</blockquote>
==Gene Mutations (SNV/INDEL)==
==Gene Mutations (SNV / INDEL)==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
==Links==
==Links==
* [[Anaplastic Large Cell Lymphoma, ALK-Negative]]
* [[HAEM5:ALK-negative anaplastic large cell lymphoma]]
* [[Anaplastic Large Cell Lymphoma, ALK-Positive]]
* [[HAEM5:ALK-positive anaplastic large cell lymphoma]]
==References==
==References==